Literature DB >> 14703101

Postlaryngectomy voice restoration using a voice prosthesis: a single institution's ten-year experience.

Antti A Mäkitie1, Riina Niemensivu, Anja Juvas, Leena-Maija Aaltonen, Leif Bäck, Hannu Lehtonen.   

Abstract

We describe the speech rehabilitation outcome of patients treated with total laryngectomy or total laryngopharyngectomy and insertion of Provox voice prostheses (Atos Medical AB, Hörby, Sweden) at the Helsinki University Central Hospital. We performed a retrospective chart review of 95 patients (88 men and 7 women; mean age, 63.5 years) who underwent insertion of a voice prosthesis in the period 1992 to 2002. Eighty-one percent (77/95) of the patients underwent a primary prosthesis insertion at the time of laryngectomy. A head and neck surgeon, a laryngologist, and a speech therapist rated the long-term tracheoesophageal speech of 78% (74/95) of the patients as good or average. The main causes for replacement of the device were obstruction, leakage or inadequate size of the prosthesis, and granulation or leakage around the fistula. According to our 10-year experience, use of the Provox prosthesis is an effective method of postlaryngectomy voice rehabilitation, and it continues to be our preferred method of voice restoration in the majority of cases.

Entities:  

Mesh:

Year:  2003        PMID: 14703101     DOI: 10.1177/000348940311201202

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  9 in total

1.  Long-term results with tracheoesophageal voice prosthesis: primary versus secondary TEP.

Authors:  Paolo Boscolo-Rizzo; Federica Zanetti; Silvia Carpené; Maria Cristina Da Mosto
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-08-23       Impact factor: 2.503

Review 2.  The development and treatment of periprosthetic leakage after prosthetic voice restoration. A literature review and personal experience part I: the development of periprosthetic leakage.

Authors:  Kai J Lorenz
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-18       Impact factor: 2.503

3.  Automatic speaking valve in speech rehabilitation for laryngectomized patients.

Authors:  Hanna Tervonen; Leif Bäck; Anja Juvas; Pirjo Räsänen; Antti A Mäkitie; Harri Sintonen; Risto P Roine; Erkki Vilkman; Leena-Maija Aaltonen
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

4.  The impact of radiotherapy and GERD on in situ lifetime of indwelling voice prostheses.

Authors:  Paolo Boscolo-Rizzo; Carlo Marchiori; Alessandro Gava; Maria Cristina Da Mosto
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-16       Impact factor: 2.503

5.  Restorative procedures in cases of impaired voice function following complete laryngectomy.

Authors:  Sven Koscielny
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-10-28

Review 6.  Post-laryngectomy voice rehabilitation with voice prosthesis: 15 years experience of the ENT Clinic of University of Catania. Retrospective data analysis and literature review.

Authors:  A Serra; P Di Mauro; D Spataro; L Maiolino; S Cocuzza
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-12       Impact factor: 2.124

Review 7.  The electrolarynx: voice restoration after total laryngectomy.

Authors:  Rachel Kaye; Christopher G Tang; Catherine F Sinclair
Journal:  Med Devices (Auckl)       Date:  2017-06-21

8.  Molecular Characterization of Fungal Colonization on the Provox™ Tracheoesophageal Voice Prosthesis in Post Laryngectomy Patients.

Authors:  Hasti Kamali Sarvestani; Roshanak Daie Ghazvini; Seyed Jamal Hashemi; Mohsen Gerami Shoar; Saham Ansari; Zahra Rafat; Aslan Ahmadi; Pedram Borghei; Miad Elahi; Abbas Rahimi Foroushani; Muhammad Ibrahim Getso; Shima Aboutalebian; Fatemeh Safari; Pegah Ardi
Journal:  Iran J Public Health       Date:  2022-01       Impact factor: 1.429

9.  Device life of the Provox Vega voice prosthesis.

Authors:  Kelli L Hancock; Nadine R Lawson; Elizabeth C Ward
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-01       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.